



NDA 022173 S-024

SUPPLEMENT APPROVAL

Eli Lilly and Company
Attention: Anindita Sen, PhD
Director, Global Regulatory Affairs – US
Lilly Corporate Center
Drop Code 2543
Indianapolis, IN 46285

Dear Dr. Sen:

Please refer to your Supplemental New Drug Application (sNDA) dated and received September 3, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zyprexa Relprevv (olanzapine) (NDA 22173) For Extended Release Injectable Suspension 210mg, 300mg, 305mg Vials.

This “Changes Being Effected” supplemental new drug application provides for the addition of the statement “Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit” to section 2.2 of labeling, Instructions to Reconstitute and Administer ZYPREXA RELPREVV.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Keith Kiedrow, PharmD, RAC, Senior Regulatory Project Manager, at (301) 796-1924.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling
REMS

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
09/17/2015